Somatostatin receptor scintigraphy in cutaneous malignant lymphomas

Journal of the American Academy of Dermatology

Volumn 34, Issue 6, 1996, Pages 985-993

  Van Den Anker Lugtenburg, P J ^a   Heule, F ^a   Vanhagen, P M ^a   Van Joost, Th ^a   Oei, H Y ^a   Lowenberg B ^a   Krenning, E P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; BONE MARROW EXAMINATION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EXAMINATION; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHADENOPATHY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCINTIGRAPHY; SKIN LYMPHOMA; TOPICAL DRUG ADMINISTRATION;

EID: 0029904374     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(96)90276-5     Document Type: Article

References (34)

1. Willemze R, Beljaards RC, Meijer CJLM. Classification of primary cutaneous T-cell lymphomas. Histopathology 1994;24:405-15.
2. Broder S, Edelson RL, Lutzner MA, et al. The Sézary syndrome:a malignant proliferation of helper T cells. J Clin Invest 1976;58:1297-306.
3. Kung PC, Berger CL, Goldstein G, et al. Cutaneous T cell lymphoma: characterization by monoclonal antibodies. Blood 1981;57:261-6.
4. Bunn PA, Poiesz BJ. Cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndrome). In: Williams WJ, Beutler E, Erslev AJ, et al, editors. Hematology. New York: McGraw-Hill, 1983:1056-66.
5. Edelson RL. Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants. J Am Acad Dermatol 1980,2:89-106.
6. Epstein EH, Levin DL, Croft JD Jr, et al. Mycosis fungoides: survival, prognostic features, response to therapy and autopsy findings. Medicine (Baltimore) 1972; 51:61-72.
7. Fuks ZY, Bagshaw MA, Farber EM. Prognostic signs and the management of the mycosis fungoides. Cancer 1973; 32:1385-95.
8. Levi JA, Wiernik PH. Management of mycosis fungoides, current status and future prospects. Medicine (Baltimore) 1975;54:73-8.
9. Bunn PA, Huberman MS, Whang-Peng J, et al. Prospective staging evaluation of patients with cutaneous T-cell lymphomas: demonstration of a high frequency of extracutaneous dissemination. Ann Intern Med 1980;93:223-30.
10. Green SB, Byar DP, Lamberg SI. Prognostic variables in mycosis fungoides. Cancer 1981;47:2671-7.
11. Fuks ZY, Castelino RA, Carmel JA, et al. Lymphography in mycosis fungoides. Cancer 1974;34:106-12.
12. Hamminga L, Mulder JD, Evans C. Staging lymphography with respect to lymph node histology, treatment, and follow-up in patients with mycosis fungoides. Cancer 1981; 47:692-7.
13. Rosen ST, Gore R, Brennan J, et al. Evaluation of computed tomography and radionuclide scanning in the staging of cutaneous T-cell lymphoma. Arch Dermatol 1986;122:884-6.
14. Escovitz ES, Soulen RL, Van Scott EJ, et al. Mycosis fungoides: a lymphographic assessment. Radiology 1974; 112:23-7.
15. Shaperoo LG, Young SW. Mycosis fungoides: manifestations on computed tomography. Radiology 1983;148:202.
16. Kulin PA, Marglin SI, Shuman WP, et al. Diagnostic imaging in the initial staging of mycosis fungoides and Sézary syndrome. Arch Dermatol 1990;126:914-8.
17. Miketic LM, Chambers TP, Lembersky BC. Cutaneous T-cell lymphoma: value of CT in staging and determining prognosis. Am J Roentgenol 1993;160:1129-32.
18. Bass JC, Korobkin MT, Cooper KD, et al. Cutaneous T-cell lymphoma: CT in evaluation and staging. Radiology 1993;186:273-8.
19. Reubi JC, Waser B, Horisberger U, et al. In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood 1993; 82:2143-51.
20. Reubi JC, Horisberger U, Waser B, et al. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 1992;103:1207-14.
21. Reubi JC, Waser B, Van Hagen PM, et al. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer 1992;50:895-900.
22. Van Hagen PM, Krenning EP, Reubi JC, et al. Somatostatin analogue scintigraphy of malignant lymphomas. Br J Haematol 1993;83:75-9.
23. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
24. Lipp RW, Silly H, Ranner G, et al. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy. J Nucl Med 1994; 36:13-8.
25. Krenning EP, Bakker WH, Kooij PPM, et al. Somatostatin receptor scintigraphy with Indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry, and comparison with Iodine-123-Tyr-3-octreotide. J Nucl Med 1992;33: 652-8.
26. 1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor positive tumors: radiolabeling and in vitro validation. Life Sci 1991;49:1583-91.
27. Rappaport H, Thomas LB. Mycosis fungoides: the pathology of extracutaneous involvement. Cancer 1974;34:1198-229.
28. Long JC, Mihm M. Mycosis fungoides with extracutaneous dissemination: a clinical pathologic entity. Cancer 1974;34:1745-55.
29. Weiss LM, Hu E, Wood GS, et al. Clonal rearrangements of T-cell receptor genes in mycosis fungoides and dermatopathic adenopathy. N Engl J Med 1985;313:539-44.
30. Whittaker SJ, Smith NP, Jones RR, et al. Analysis of β, γ, and δ T-cell receptor genes in mycosis fungoides and Sézary syndrome. Cancer 1991;68:1572-82.
31. Scheffer G, Meijer CJLM, van Vloten WA. Dermatopathic lymphadenopathy and lymph node involvement in mycosis fungoides. Cancer 1980;45:137-48.
32. Schonbrunn A. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology 1982;110:1147-54.
33. Viguerie N, Estève JP, Susini C. Dexamethasone effects on somatostatin receptors in pancreatic acinar AR4-2J cells. Biochem Biophys Res Commun 1987;147:942-8.
34. Witzig TE, Letendre L, Gerstner J, et al. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group Trial. J Clin Oncol 1995;13:2012-15.